Influence of sirolimus-loaded nanoparticles on physiological functions of native human polymorphonuclear neutrophils

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 8, 2012, Pages 1293-1300

  Moeller, Sandra ^a   Kegler, Ricarda ^a   Sternberg, Katrin ^a   Mundkowski, Ralf G ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Nanoparticle; PLA; PMN; Rapamycin; Sirolimus

Indexed keywords

BLOOD LEVELS; CYTOKINES; DRUG CARRIER; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG-TARGETING; FLUORESCENT PROPERTY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE AGENT; INTRACELLULAR CONCENTRATION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; PHAGOCYTIC ACTIVITY; PHYSIOLOGICAL FUNCTIONS; PLA; PMN; POLY (D ,L-LACTIDE); POLYMORPHONUCLEAR NEUTROPHILS; RAPAMYCIN; SIDE EFFECT; SIROLIMUS; ULTRA-TRACE ANALYSIS;

BIOCHEMISTRY; BLOOD; DRUG DELIVERY; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE; ORGANIC POLYMERS; PHYSIOLOGY; TRACE ANALYSIS;

NANOPARTICLES;

FLUORESCENT DYE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; NANOPARTICLE; POLYLACTIDE; RAPAMYCIN;

ADULT; ARTICLE; CELL FUNCTION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NORMAL HUMAN; PHAGOCYTOSIS; RESPIRATORY BURST;

ADAPTIVE IMMUNITY; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NANOPARTICLES; NEUTROPHILS; PARTICLE SIZE; POLYESTERS; POLYETHYLENE GLYCOLS; SIROLIMUS; SOLUBILITY;

EID: 84867883168     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.01.011     Document Type: Article

References (50)

1. Salata O. Applications of nanoparticles in biology and medicine. J Nanobiotechnol 2004, 2:3.
2. Zhang L., Gu F.X., Chan J.M., Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008, 83:761-769.
3. Weisz G., Leon M.B., Holmes D.R., Kereiakes D.J., Popma J.J., Teirstein P.S., et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol 2009, 53:1488-1497.
4. Morice M.C., Serruys P.W., Barragan P., Bode C., Van Es G.A., Stoll H.P., et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 2007, 50:1299-1304.
5. Rensing B.J., Vos J., Smits P.C., Foley D.P., van den Brand M.J., van der Giessen W.J., et al. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J 2001, 22:2125-2130.
6. Tanabe K., Degertekin M., Regar E., Ligthart J.M., van der Giessen W.J., Serruys P.W. No delayed restenosis at 18 months after implantation of sirolimus-eluting stent. Catheter Cardiovasc Interv 2002, 57:65-68.
7. Sehgal S.N. Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995, 17:660-665.
8. Yatscoff R., LeGatt D., Keenan R., Chackowsky P. Blood distribution of rapamycin. Transplantation 1993, 56:1202-1206.
9. Marx S.O., Jayaraman T., Go L.O., Marks A.R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995, 76:412-417.
10. Dobrovolskaia M.A., Aggarwal P., Hall J.B., McNeil S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 2008, 5:487-495.
11. Sant S., Poulin S., Hildgen P. Effect of polymer architecture on surface properties, plasma protein adsorption, and cellular interactions of pegylated nanoparticles. J Biomed Mater Res A 2008, 87:885-895.
12. Yuan X.B., Yuan Y.B., Jiang W., Liu J., Tian E.J., Shun H.M., et al. Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int J Pharm 2008, 349:241-248.
13. Zweers M.L., Engbers G.H., Grijpma D.W., Feijen J. Release of anti-restenosis drugs from poly(ethylene oxide)-poly(dl-lactic-co-glycolic acid) nanoparticles. J Control Release 2006, 114:317-324.
14. Luderer F., Lobler M., Rohm H.W., Gocke C., Kunna K., Kock K., et al. Biodegradable sirolimus-loaded poly(lactide) nanoparticles as drug delivery system for the prevention of in-stent restenosis in coronary stent application. J Biomater Appl 2011, 25:851-875.
15. Kanchan V., Panda A.K. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 2007, 28:5344-5357.
16. 14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 1992, 13:1093-1102.
17. Gee I., Trull A.K., Charman S.C., Alexander G.J. Sirolimus inhibits oxidative burst activity in transplant recipients. Transplantation 2003, 76:1766-1768.
18. Gibaud S., Demoy M., Andreux J.P., Weingarten C., Gouritin B., Couvreur P. Cells involved in the capture of nanoparticles in hematopoietic organs. J Pharm Sci 1996, 85:944-950.
19. Verrecchia T., Spenlehauer G., Bazile D., Murry-Brelier A., Archimbaud Y., Veillard M. Non-stealth (poly(lactic acid/albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers. J Control Release 1995, 36:49-61.
20. Zambaux M.F., Faivre-Fiorina B., Bonneau F., Marchal S., Merlin J.L., Dellacherie E., et al. Involvement of neutrophilic granulocytes in the uptake of biodegradable non-stealth and stealth nanoparticles in guinea pig. Biomaterials 2000, 21:975-980.
21. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997, 28:5-24.
22. Mo Y., Zhu X., Hu X., Tollerud D.J., Zhang Q. Cytokine and NO release from peripheral blood neutrophils after exposure to metal nanoparticles: in vitro and ex vivo studies. Nanotoxicology 2008, 2:79-87.
23. Buret A.G. Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin. Can J Vet Res 2010, 74:1-10.
24. Gomez-Cambronero J. Rapamycin inhibits GM-CSF-induced neutrophil migration. FEBS Lett 2003, 550:94-100.
25. Shen H., Wu G., Liu G., Ma H., Liao A., Zhao Y. Effects of rapamycin on the differentiation and function of macrophages in vitro. Agr Sci China 2009, 8:620-627.
26. Wessely R., Blaich B., Belaiba R.S., Merl S., Gorlach A., Kastrati A., et al. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. Thromb Haemost 2007, 97:1003-1012.
27. Woltman A.M., de Fijter J.W., Kamerling S.W., van Der Kooij S.W., Paul L.C., Daha M.R., et al. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 2001, 98:174-180.
28. Filipe V., Hawe A., Jiskoot W. Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 2010, 27:796-810.
29. Altman S.A., Randers L., Rao G. Comparison of trypan blue dye exclusion and fluorometric assays for mammalian cell viability determinations. Biotechnol Prog 1993, 9:671-674.
30. Paegelow I., Trzeczak S., Bockmann S., Vietinghoff G. Migratory responses of polymorphonuclear leukocytes to kinin peptides. Pharmacology 2002, 66:153-161.
31. Maderazo E.G., Woronick C.L. Micropore filter assay of human granulocyte locomotion: problems and solutions. Clin Immunol Immunopathol 1978, 11:196-211.
32. US Department of Health and Human Services (US DHHS), US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM) Guidance for industry: bioanalytical method validation 2001, 1-25. US DHHS, Rockville (MD).
33. Naess A., Stenhaug Kilhus K., Nystad T.W., Sornes S. Linezolid and human polymorphonuclear leukocyte function. Chemotherapy 2006, 52:122-124.
34. Fantoni M., Tamburrini E., Pallavicini F., Antinori A., Nervo P. Influence of ofloxacin and pefloxacin on human lymphocyte immunoglobulin secretion and on polymorphonuclear leucocyte superoxide anion production. J Antimicrob Chemother 1988, 22:93-96.
35. Andersson J., Dahlgren U.I. Effect of 2-hydroxyethyl-methacrylate (HEMA) on the phagocytic and respiratory burst activity of human neutrophils and monocytes. Eur J Oral Sci 2008, 116:369-374.
36. Hosoi H., Dilling M.B., Liu L.N., Danks M.K., Shikata T., Sekulic A., et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 1998, 54:815-824.
37. Gref R., Luck M., Quellec P., Marchand M., Dellacherie E., Harnisch S., et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 2000, 18:301-313.
38. Mosquera J.A., Hernandez J.P., Valero N., Espina L.M., Anez G.J. Ultrastructural studies on dengue virus type 2 infection of cultured human monocytes. Virol J 2005, 2:26.
39. Berkow R.L., Dodson R.W. Volume-dependent polymorphonuclear leukocytes fractions isolated by counterflow centrifugal elutriation: PMN volume does not correlate with PMN age. J Leukoc Biol 1987, 41:518-526.
40. Harush-Frenkel O., Debotton N., Benita S., Altschuler Y. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem Biophys Res Commun 2007, 353:26-32.
41. 4 nanoparticles in vitro. J Mater Sci Mater Med 2007, 18:2145-2149.
42. Jordan A., Scholz R., Wust P., Schirra H., Schiestel T., Schmidt H., et al. Endocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma cells in vitro. J Magn Magn Mater 1999, 194:185-196.
43. Chen J.H., Shagufta M., Davis S.S. Preparation and characterization of prednisolone-poly (hydroxybutyrate-co-hydroxyvalerate) nanoparticles. Yao Xue Xue Bao 2002, 37:473-476.
44. Oyler A.R., Armstrong B.L., Dunphy R., Alquier L., Maryanoff C.A., Cohen J.H., et al. Mass balance in rapamycin autoxidation. J Pharm Biomed Anal 2008, 48:1368-1374.
45. Haddadi A., Elamanchili P., Lavasanifar A., Das S., Shapiro J., Samuel J. Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells. J Biomed Mater Res A 2008, 84:885-898.
46. + progenitor-derived dendritic cells. J Biomed Mater Res A 2008, 85:983-992.
47. Cassatella M.A. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995, 16:21-26.
48. Webb S. The role of mediators in sepsis resolution. Adv Sepsis 2002, 2:8-14.
49. Kurt-Jones E.A., Mandell L., Whitney C., Padgett A., Gosselin K., Newburger P.E., et al. Role of Toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils. Blood 2002, 100:1860-1868.
50. Barnett M.L., Lamb K.A., Costello K.M., Pike M.C. Characterization of interleukin-8 receptors in human neutrophil membranes: regulation by guanine nucleotides. Biochim Biophys Acta 1993, 1177:275-282.